Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Tarceva (erlotinib) - Important Safety Information from Roche Products (Ireland) Ltd. as approved by the HPRA
Notice type:
3rd Party Publications
Date:
15/01/2016
Problem Or Issue:
Important Safety Information communication from Roche Products (Ireland) Ltd. - Tarceva (erlotinib): First line maintenance indication now restricted to treatment of patients whose tumors harbour an EGFR-activing mutation.
Important Safety Information - Tarceva (erlotinib)
« Back
Date Printed: 26/04/2024